1. INTRODUCTION
1.1. Market Overview
1.2. Market Definition
1.3. Scope of the Study
1.4. Market Segmentation
1.5. Currency
1.6. Assumptions
1.7. Base and Forecast Years Timeline
1.8. Key Benefits for the Stakeholders
2. RESEARCH METHODOLOGY
2.1. Research Design
2.2. Research Process
3. EXECUTIVE SUMMARY
3.1. Key Findings
3.2. Analyst View
4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Forces Analysis
4.3.1. Bargaining Power of Supplier
4.3.2. Bargaining Power of Buyers
4.3.3. The Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis
5. SUBCUTANEOUS DRUG DELIVERY MARKET BY PRODUCT TYPE
5.1. Introduction
5.2. Prefilled syringes
5.3. Pen injector
5.4. Auto injectors
5.5. Wearable injectors
5.6. Needle-free Injectors
6. SUBCUTANEOUS DRUG DELIVERY MARKET BY APPLICATION
6.1. Introduction
6.2. Diabetes
6.3. Fertility
6.4. Oncology
6.5. Others
7. SUBCUTANEOUS DRUG DELIVERY MARKET BY END-USERS
7.1. Introduction
7.2. Hospitals and Clinics
7.3. Homecare Settings
7.4. Ambulatory Surgical Centers
8. SUBCUTANEOUS DRUG DELIVERY MARKET BY GEOGRAPHY
8.1. Introduction
8.2. North America
8.2.1. USA
8.2.2. Canada
8.2.3. Mexico
8.3. South America
8.3.1. Brazil
8.3.2. Argentina
8.3.3. Others
8.4. Europe
8.4.1. UK
8.4.2. Germany
8.4.3. France
8.4.4. Italy
8.4.5. Others
8.5. Middle East and Africa
8.5.1. Saudi Arabia
8.5.2. Israel
8.5.3. Others
8.6. Asia Pacific
8.6.1. Japan
8.6.2. China
8.6.3. India
8.6.4. South Korea
8.6.5. Indonesia
8.6.6. Thailand
8.6.7. Others
9. COMPETITIVE ENVIRONMENT AND ANALYSIS
9.1. Major Players and Strategy Analysis
9.2. Market Share Analysis
9.3. Mergers, Acquisitions, Agreements, and Collaborations
9.4. Competitive Dashboard
10. COMPANY PROFILES
10.1. Gerresheimer AG
10.2. Ypsomed AG
10.3. Medtronic Plc
10.4. Sanofi
10.5. Novo Nordisk
10.6. Becton, Dickinson and Company
10.7. Elcam Medical Group
10.8. Unilife Corporation
10.9. Insulet Corporation
10.10. Eli Lilly and Company